Preferred Label : vecuronium bromide;

MeSH definition : Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.;

MeSH synonym : hydrobromide, vecuronium; bromide, vecuronium; vecuronium hydrobromide;

MeSH Hyperonym : Vecuronium;

MeSH hyponym : NC-45; norcuron; vecuronium bromide, quaternary ion; NC 45; NC45; ORG-NC45; ORG NC45; ORG-NC 45; ORG NC 45; ORGNC 45; ORG-NC-45; ORGNC45;

Related MeSH term : vecuronium citrate; vecuronium phosphate; vecuronium maleate; vecuronium hydrochloride; Phosphate, Vecuronium; Citrate, Vecuronium; Hydrochloride, Vecuronium; Maleate, Vecuronium;

MeSH CAS label : piperidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl)-1-methyl-, bromide;

MeSH Related Number : vecuronium hydrochloride; vecuronium maleate; vecuronium phosphate; vecuronium bromide, quaternary ion; vecuronium citrate; 50700-72-6 (Vecuronium bromide); 74531-68-3 (citrate); 74531-71-8 (phosphate); 74531-75-2 (HBr); 74531-76-3 (maleate); 74551-98-7 (HCl); 86029-43-8 (quaternary ion); vecuronium; 5438723848;

Registry Number MeSH : 50700-72-6;

Related CAS MeSH : 74551-98-7 (Vecuronium hydrochloride); 74531-76-3 (Vecuronium maleate); 74531-71-8 (Vecuronium phosphate); 86029-43-8 (Vecuronium bromide, quaternary ion); 74531-68-3 (Vecuronium citrate); 5438723848 (Vecuronium);

Wikipedia link : https://en.wikipedia.org/wiki/Vecuronium bromide;

Codes EINECS : 256-723-9;

Is substance : O;

UNII : 7E4PHP5N1D;

InChIKey : VEPSYABRBFXYIB-PWXDFCLTSA-M;

Details


Main resources

You can consult :

Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.

Summary Basis of Decision (SBD) for Bridion
Sugammadex sodium, 100 mg/mL, solution, intravenous
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00283
2016
false
false
false
Canada
French
English
summary of product characteristics
Sugammadex sodium
Sugammadex sodium
injections, intravenous
sugammadex
vecuronium bromide
neuromuscular nondepolarizing agents
anesthesia recovery period
Neuromuscular blockade reversal
adult
risk assessment
neuromuscular blockade
gamma-cyclodextrins
gamma-cyclodextrins
androstanols
Sugammadex
Sugammadex
Rocuronium

---
https://www.ema.europa.eu/medicines/human/EPAR/Bridion
2012
United Kingdom
French
English
syndication feed
gamma-cyclodextrins
gamma-cyclodextrins
antidotes
drug approval
drug labeling
treatment outcome
injections, intravenous
adult
child
adolescent
vecuronium bromide
neuromuscular nondepolarizing agents
androstanols
anesthesia recovery period
respiratory muscles
neuromuscular blockade
aged
monitoring, physiologic
drug interactions
breast feeding
drug evaluation, preclinical
antidotes
pregnancy
drug incompatibility
drug storage
drug compounding
sugammadex
androstanols
gamma-cyclodextrins
package leaflet
drug evaluation
summary of product characteristics
Sugammadex
Sugammadex
Rocuronium

---
Nous contacter.
26/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.